Elicit: CD80/CD86 Blockade and T-Cell Dynamics
How does CD80/CD86 blockade by abatacept affect T-cell activation and tolerance?
Abstract
CD80/CD86 blockade by abatacept consistently reduces T-cell activation across multiple disease contexts through selective modulation of CD28-mediated costimulation. Treatment decreases expression of activation markers (CD38, ICOS, Ki-67) and reduces proliferation particularly in CD4+ T cells, with 7-10-fold fewer proliferating and activated effector memory CD4+ T cells observed in GVHD prevention. Abatacept shifts CD4+ compartments toward naive phenotypes while reducing central memory populations, with transcriptional analysis revealing decreased expression of genes regulating cell cycle and chromatin dynamics. CD8+ T-cell subsets remain relatively resistant to these effects, indicating lesser reliance on CD28 costimulation. The effects are reversible after treatment discontinuation, indicating that abatacept maintains an altered immune state through continuous pharmacological inhibition rather than inducing permanent tolerance.
Methods
We analyzed 10 sources from an initial pool of 200, using 8 screening criteria. Each paper was reviewed for 8 key aspects that mattered most to the research question.
Results
Characteristics of Included Studies
| Study | Disease context | Study design | Abatacept regimen | Primary T-cell measures |
|---|---|---|---|---|
| J. Kremer et al., 2006 | Rheumatoid arthritis with inadequate methotrexate response | Randomized, double-blind, placebo-controlled trial | ~10 mg/kg IV monthly for 1 year | Not specified |
| M. Weisman et al., 2006 | Active rheumatoid arthritis with inadequate methotrexate response | Phase II trial | 10 mg/kg or 2 mg/kg for 12 months | Inflammatory biomarkers (IL-6, soluble IL-2 receptor) |
| Divya Koura et al., 2013 | Acute GVHD prevention during unrelated-donor HCT | First-in-disease trial | 10 mg/kg IV on days -1, +5, +14, +28 post-HCT | Ki-67 proliferation, CD38/HLA-DR activation, FoxP3+ Tregs |
| M. Eichmann et al., 2020 | New-onset type 1 diabetes | Clinical trial | Not specified | CD4+ and CD8+ naive and memory subsets by flow/mass cytometry |
| R. Alten, 2007 | Rheumatoid arthritis unresponsive to DMARDs or TNF-blockers | Review of trials | ~10 mg/kg at weeks 0, 2, 4, then every 4 weeks for 6-12 months | Not specified |
| T. Orbán et al., 2014 | Recent-onset type 1 diabetes | Phase 2 trial | 10 mg/kg IV every 28 days for 24 months | CM and naive CD4 T cells, CD4+CD25high Tregs, CD69 activation |
| A. Parulekar et al., 2013 | Mild atopic asthma | Randomized, placebo-controlled, double-blind trial | 3 months of treatment | Naive vs. memory CD4+ T cells |
| B. Watkins et al., 2021 | Severe acute GVHD following unrelated-donor HCT | Phase II trial | CNI/MTX plus abatacept, measured at day +100 and +180 | T-cell activation (method not specified) |
| S. Glatigny et al., 2019 | Relapsing-remitting multiple sclerosis | Phase II, double-blind, placebo-controlled trial | Weeks 0, 2, 4, then every 4 weeks through week 24 | Tfh and Treg frequency, CD38/ICOS activation, transcriptional profiling |
| M. Bonelli et al., 2016 | Rheumatoid arthritis | In vivo clinical analysis and ex vivo experiments | Not specified | Treg frequency/function, CD95 expression, activation markers |
Effects on T-cell Activation
Activation Marker Expression
Abatacept treatment reduced expression of multiple T-cell activation markers across disease contexts. In GVHD prevention, CD4+ T cells showed 7-fold fewer proliferating cells (Ki-67+) and 10-fold fewer activated cells (CD38+/HLA-DR+) at day +28 compared to controls, with effects concentrated in effector memory populations. In multiple sclerosis, abatacept decreased the proportion of CD38+ and ICOS+ activated cells within both T follicular helper (Tfh) and regulatory T cell populations. Rheumatoid arthritis patients exhibited downregulation of activation-associated markers and CD95 on CD4+ T cells and Tregs.
The activation changes were selective for certain T-cell populations. CD4+ T cells were consistently more affected than CD8+ T cells across studies. In type 1 diabetes, CD4+ conventional and regulatory subsets showed altered frequencies while CD8+ subsets remained relatively resistant, indicating lesser reliance on CD28-mediated costimulation in CD8+ cells.
Proliferation and Cell Cycle Effects
Transcriptional analysis revealed that abatacept disrupted cell cycle and proliferation pathways in activated T cells, directly linking reduced costimulatory signaling to impaired activation and proliferation.
Inflammatory Biomarkers
Beyond cellular activation markers, abatacept reduced soluble inflammatory mediators associated with T-cell activation. These systemic changes reflected the anti-inflammatory and immunomodulatory effects of selective CD28 costimulation blockade.
Effects on T-cell Subset Distribution
| Study | Context | Naive T cells | Memory T cells | Specialized subsets | Effect magnitude |
|---|---|---|---|---|---|
| T. Orbán et al., 2014 | Type 1 diabetes | Increased naive CD4+ T cells | Decreased central memory CD4+ T cells | Reduced CD4+CD25high Tregs | Significant reduction in absolute CM numbers |
| M. Eichmann et al., 2020 | Type 1 diabetes | Ag-naive subsets increase | Ag-experienced subsets decrease | Not specified | CD4+ affected, CD8+ not affected |
| A. Parulekar et al., 2013 | Asthma | Increased naive CD4+ T cells | Decreased memory CD4+ T cells | Not specified | Not quantified |
| S. Glatigny et al., 2019 | Multiple sclerosis | No effect on CD45RA+ naive Tregs | Decreased CD45RO+ memory Tregs | Decreased Tfh frequency; reduced CD38+/ICOS+ activation | Progressive Tfh decline |
| M. Bonelli et al., 2016 | Rheumatoid arthritis | Not specified | Not specified | Increased Treg numbers; diminished Treg suppressive function | Not quantified |
Abatacept consistently shifted CD4+ T-cell compartments toward naive phenotypes while reducing memory populations.
Effects on Regulatory T Cells and Tolerance
Abatacept’s effects on regulatory T cells varied by subset and assay. In rheumatoid arthritis, total Treg numbers increased after treatment initiation, but functional suppression assays revealed diminished capacity to suppress responder T-cell proliferation.
Temporal Dynamics of Effects
| Study | Context | Onset of activation effects | Peak effects | Reversibility | Duration assessed |
|---|---|---|---|---|---|
| Divya Koura et al., 2013 | GVHD | Day +28 | Day +28 | Yes, effects diminished after treatment cessation | Through day +100 |
| T. Orbán et al., 2014 | Type 1 diabetes | Within first 6 months | 6, 12, and 24 months | Yes, returned to baseline 6 months post-treatment | 30 months (24 + 6 follow-up) |
| S. Glatigny et al., 2019 | Multiple sclerosis | Treg changes at 4 weeks; Tfh at 16 weeks | Not specified | Yes, reversed upon discontinuation | 52 weeks |
| J. Kremer et al., 2006 | Rheumatoid arthritis | By 6 months (clinical effects) | Up to 1 year | Not assessed | 1 year |
Mechanistic Insights into Activation vs. Tolerance
Abatacept’s mechanism extends beyond simple CD80/CD86 blockade to affect multiple cellular processes. Transcriptional profiling revealed that abatacept decreased expression of genes regulating cell cycle and chromatin dynamics.
Study Quality and Limitations
Several factors affect interpretation of these findings across studies. Sample size limitations were notable, particularly for immunological endpoints.
Synthesis
The evidence reveals a consistent pattern: abatacept reduces T-cell activation markers and shifts CD4+ compartments toward naive phenotypes while showing limited effects on CD8+ cells. However, the relationship between these immunological changes and clinical outcomes varies substantially across diseases, warranting careful examination.